n.a. (PCYC)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Small-Caps Hold Their Ground

Profit-taking hits the big-name indices while the Russell 2000 hangs tough.

PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower

PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Midday Movers: Biotech Bullishness Trumps Uncertainty Over ISM Numbers: StockTwits.com

Midday Movers: Biotech Bullishness Trumps Uncertainty Over ISM Numbers: StockTwits.com

Investors on StockTwits.com ignored corrected manufacturing data in favor of news from biotech companies.

Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits

Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits

These biotechs are making big waves, as Apple's Worldwide Developers Conference will likely be a washout.

Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients

Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients

Pharmacyclics and Johnson & Johnson's blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline's Arzerra when used to treat elderly patients with relapsed chronic lymphocytic leukemia, according to results from a phase III study released today at the American Society of Clinical Oncology (ASCO) annual meeting.

ASCO '14: What's on Tap for Saturday

ASCO '14: What's on Tap for Saturday

Featured data presentations from Eli Lilly, Pharmacyclics and Clovis Oncology on the Saturday menu for the biggest cancer conference in the world.

'Fast Money' Recap: What's On? How About Netflix Stock?

'Fast Money' Recap: What's On? How About Netflix Stock?

The trading panel discussed Netflix's valuation and whether shares are worth buying.

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Will This Downgrade Hurt Pharmacyclis (PCYC) Stock Today?

Will This Downgrade Hurt Pharmacyclis (PCYC) Stock Today?

RBC Capital downgrades Pharmacyclis (PCYC) to 'sector perform' from 'outperform,' saying the company is facing potential growth headwinds.

The Bull Thesis for Pharmacyclics Into ASCO '14

The Bull Thesis for Pharmacyclics Into ASCO '14

If we get complete response rates from Imbruvica-Arzerra similar to what's being reported for Abbvie's ABT-199, that would be positive for Pharmacyclics

ASCO '14 Preview: Blood Cancer Data from Pharmacyclics, Gilead, Abbvie

ASCO '14 Preview: Blood Cancer Data from Pharmacyclics, Gilead, Abbvie

All three companies will be presented updates results on drugs used to treat chronic lymphocytic leukemia.

The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure

The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure

The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.

'Mad Money' Lightning Round: Valero Is Amazing

'Mad Money' Lightning Round: Valero Is Amazing

Cramer does not like Plug Power but he wants Old Republic International.

Jim Cramer's 'Mad Money' Recap: Market Headwinds Getting Worse

Jim Cramer's 'Mad Money' Recap: Market Headwinds Getting Worse

Investors are just as likely to lose money as they are to make money on any given day, and there are a host of good reasons why, Cramer says.

'Mad Money' Lightning Round: Blackstone Is On Fire!

'Mad Money' Lightning Round: Blackstone Is On Fire!

Cramer doesn't like Gigamon and Southwest Airlines but he's buying Pharmacyclics.

Jim Cramer's 'Mad Money' Recap: Don't Blame the Companies

Jim Cramer's 'Mad Money' Recap: Don't Blame the Companies

There's a lot wrong with this market but the companies are part of the solution, not the problem, Cramer asserts.

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful

Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.

Three Oversold BioTechs for Tired Gamblers: StockTwits.com

Three Oversold BioTechs for Tired Gamblers: StockTwits.com

Investors seek to play with big-name biotechs after this month's sell-off in the sector. Here are three names that don't promise the lottery payouts of successful small caps, but don't demand betting the house on one drug awaiting approval.

'Mad Money' Lightning Round: VMware Is the One to Own

'Mad Money' Lightning Round: VMware Is the One to Own

Cramer wants you to buy more Celgene at $140 and thinks Bluebird Bio is going higher.

Jim Cramer's 'Mad Money' Recap: Did You Panic Wednesday? Too Bad

Jim Cramer's 'Mad Money' Recap: Did You Panic Wednesday? Too Bad

You missed out on substantial gains, particularly in financials and technology, Cramer says.

Jim Cramer: Happy Birthday, You Bogus Bull Market

Jim Cramer: Happy Birthday, You Bogus Bull Market

You've rallied 177%, yet many don't seem to believe you exist.

Low Expectations for Friday Expiration

Wednesday's selloff dampened bullish sentiment and triggered a chunk of technical damage, but bears still found a way to lose control of the tape.

Who Is Responsible for Biotech's Torrid Start to 2014?

Who Is Responsible for Biotech's Torrid Start to 2014?

Biotech investing goes mainstream.

Gilead Sciences: Lack of Hep C Sales Guidance Doesn't Blemish Strong Year Ahead

Gilead Sciences: Lack of Hep C Sales Guidance Doesn't Blemish Strong Year Ahead

Expectations for Gilead's Hep C pill Sovaldi and follow-on therapies remain high in 2014 and beyond.

Nothing to Gain from this Dangerous Tape

The best strategy now is to go into stalker mode and wait to pick up strong stocks at value prices.

Where Upside Surprises Could Be Percolating

For these names, targets have climbed ahead of earnings releases.

Here's a Sign of Health

These growth stocks are no longer an anchor to this market.

First Week Of August 16th Options Trading For Pharmacyclics (PCYC)

First Week Of August 16th Options Trading For Pharmacyclics (PCYC)

Investors in Pharmacyclics, Inc. saw new options begin trading this week, for the August 16th expiration.

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The list of biotech and drug stocks with billion-dollar market values almost doubled in 2013 -- a sign that investors loved speculation and were rewarded for it.

January 2014 Options Now Available For Pharmacyclics (PCYC)

January 2014 Options Now Available For Pharmacyclics (PCYC)

Investors in Pharmacyclics, Inc. saw new options begin trading today, for the January 2014 expiration.